{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:11:08Z","timestamp":1782569468291,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The meta-analysis was to evaluate the therapeutic benefits of neoadjuvant chemotherapy (NACT), primarily consisting of platinum-based regimens in conjunction with paclitaxel, when integrated with concurrent chemoradiotherapy (CCRT) for individuals afflicted with locally advanced cervical cancer (LACC). The outcomes were determined by overall survival (OS), progression-free survival (PFS), complete response rate (CRR), objective response rate, recurrence rate and adverse events. The assessment of these outcomes was based on the relative risk (RR) accompanied by its 95% confidence interval (CI). Eight articles were included for analysis. LACC patients who underwent treatment with paclitaxel combined with cisplatin (TP)-based NACT in conjunction with CCRT demonstrated improved OS at 2 (RR: 1.11, 95% CI: 1.07, 1.16, P\u2009&amp;lt;\u20090.001), 3 (RR: 1.30, 95% CI: 1.23, 1.37, P\u2009&amp;lt;\u20090.001) and 5\u00a0years (RR: 1.20, 95% CI: 1.10, 1.32, P\u2009&amp;lt;\u20090.001), as well as PFS at 1 (RR: 1.03, 95% CI: 1.00, 1.06, P\u2009=\u00a00.035), 2 (RR: 1.21, 95% CI: 1.04, 1.40, P\u2009=\u20090.012), 3 (RR: 1.26, 95% CI: 1.17, 1.34, P\u2009&amp;lt;\u20090.001) and 5 (RR: 1.39, 95% CI: 1.25, 1.55, P\u2009&amp;lt;\u20090.001) years, when compared with patients who received CCRT alone. Moreover, the TP-based NACT in conjunction with CCRT achieved a higher CRR and exhibited a lower rate of disease recurrence (RR:1.28, 95% CI:1.08, 1.50, P\u2009=\u20090.003). No significant differences in the risk of adverse effects including anemia, leukopenia, thrombocytopenia, radiocystitis and radiation enteritis between the group treated with TP-based NACT combined with CCRT and the group treated with CCRT alone were observed. The combination of TP-based NACT and CCRT demonstrates superior clinical efficacy than CCRT alone. This study may contribute to reducing the burden of LACC by using TP-based NACT plus CCRT.<\/jats:p>","DOI":"10.1093\/jrr\/rrae073","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:31:47Z","timestamp":1728293507000},"page":"733-743","source":"Crossref","is-referenced-by-count":8,"title":["Clinical efficacy and safety of neoadjuvant chemotherapy with paclitaxel and cisplatin in combination with concurrent chemoradiotherapy for locally advanced cervical cancer: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"65","author":[{"given":"Penpa","family":"Yeshe","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology , Shanghai East Hospital, School of Medicine, , No. 150, Jimo Road, Pudong New Area, Shanghai 200120 ,","place":["P.R. China"]},{"name":"Tongji University , Shanghai East Hospital, School of Medicine, , No. 150, Jimo Road, Pudong New Area, Shanghai 200120 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Shanghai East Hospital, School of Medicine, , No. 150, Jimo Road, Pudong New Area, Shanghai 200120 ,","place":["P.R. China"]},{"name":"Tongji University , Shanghai East Hospital, School of Medicine, , No. 150, Jimo Road, Pudong New Area, Shanghai 200120 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"key":"2024121018540896600_ref1","doi-asserted-by":"publisher","first-page":"200238","DOI":"10.1016\/j.tvr.2022.200238","article-title":"Cervical cancer therapies: current challenges and future perspectives","volume":"13","author":"Burmeister","year":"2022","journal-title":"Tumour Virus Res"},{"key":"2024121018540896600_ref2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/aog.0000000000003311","article-title":"Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines","volume":"134","author":"Wright","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2024121018540896600_ref3","doi-asserted-by":"publisher","first-page":"Cd010260","DOI":"10.1002\/14651858.CD010260.pub3","article-title":"Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer","volume":"8","author":"Kokka","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2024121018540896600_ref4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s0140-6736(18)32470-x","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"2024121018540896600_ref5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12885-023-10517-x","article-title":"Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"2024121018540896600_ref6","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/1097-0142(19821115)50:10&lt;1979::aid-cncr2820501002&gt;3.0.co;2-d","article-title":"Clinical cancer research: an embattled species","volume":"50","author":"Frei","year":"1982","journal-title":"Cancer"},{"key":"2024121018540896600_ref7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.tjog.2021.03.008","article-title":"Neoadjuvant chemotherapy increases the 5-year overall survival of patients with resectable cervical cancer: a systematic review and meta-analysis","volume":"60","author":"Xu","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2024121018540896600_ref8","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.3802\/jgo.2024.35.e10","article-title":"Improving the efficacy and safety of concurrent chemoradiotherapy by neoadjuvant chemotherapy: a randomized controlled study of locally advanced cervical cancer with a large tumor","volume":"35","author":"Li","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"2024121018540896600_ref9","doi-asserted-by":"publisher","first-page":"3124-+","DOI":"10.1200\/jco.19.00674","article-title":"Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer: a randomized phase II trial","volume":"37","author":"Costa","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024121018540896600_ref10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/s1470-2045(23)00147-x","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"key":"2024121018540896600_ref11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1586\/14737140.2015.1079777","article-title":"Neoadjuvant chemotherapy in cervical cancer: an update","volume":"15","author":"Lapresa","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"2024121018540896600_ref12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024121018540896600_ref13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"2024121018540896600_ref14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2024121018540896600_ref15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s13224-019-01236-0","article-title":"Comparative study of neoadjuvant chemotherapy followed by definitive chemoradiotherapy versus definitive chemoradiotherapy alone in locally advanced carcinoma of cervix","volume":"69","author":"Tripathi","year":"2019","journal-title":"J Obstet Gynaecol India"},{"key":"2024121018540896600_ref16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ygyno.2012.01.033","article-title":"Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma","volume":"125","author":"Tang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"2024121018540896600_ref17","first-page":"1066","article-title":"Clinical outcomes of surgery following neoadjuvant chemotherapy with cisplatin and irinotecan versus concurrent chemoradiotherapy for the treatment of cervical cancer","volume":"33","author":"Zhong","year":"2020","journal-title":"Heilongjiang Med J"},{"key":"2024121018540896600_ref18","first-page":"2530","article-title":"Observational study on the clinical efficacy of neoadjuvant chemotherapy in cervical cancer","volume":"25","author":"Jiang","year":"2014","journal-title":"Mod Diagn Treat"},{"key":"2024121018540896600_ref19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.13390\/j.issn.1672-1861.2019.03.012","article-title":"The treatment effect of neoadjuvant chemotherapy followed by concurrent chemoradiation in locallyadvanced cervical cancer","volume":"20","author":"Li","year":"2019","journal-title":"Chin J Clin Obstet Gynecol"},{"key":"2024121018540896600_ref20","article-title":"Neoadjuvant chemotherapy and concurrent chemoradiotherapy for 48 patients with locallyadvanced cervical cancer","volume":"35","author":"Tian","year":"2017","journal-title":"J Guangdong Med Univ"},{"key":"2024121018540896600_ref21","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.21873\/anticanres.14346","article-title":"A phase II study of neoadjuvant chemotherapy followed by extended field concurrent chemoradiotherapy for para-aortic lymph node positive cervical cancer","volume":"40","author":"Shimoji","year":"2020","journal-title":"Anticancer Res"},{"key":"2024121018540896600_ref22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13224-015-0698-5","article-title":"Pros and cons of adding of neoadjuvant chemotherapy to standard concurrent chemoradiotherapy in cervical cancer: a regional cancer center experience","volume":"66","author":"Narayan","year":"2016","journal-title":"J Obstet Gynaecol India"},{"key":"2024121018540896600_ref23","first-page":"42","article-title":"Long-term survival following neoadjuvant chemotherapy and concomitant radiochemotherapy in locally advanced cervical cancer: results of the Oncology Institute ``Prof Dr. Ion Chiricuta'' experience","volume":"11","author":"Marita","year":"2018","journal-title":"J Med Life"},{"key":"2024121018540896600_ref24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ygyno.2013.01.011","article-title":"Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study","volume":"129","author":"Singh","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2024121018540896600_ref25","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/bjc.2013.230","article-title":"A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer","volume":"108","author":"McCormack","year":"2013","journal-title":"Br J Cancer"},{"key":"2024121018540896600_ref26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4081\/oncol.2014.250","article-title":"The role of neoadjuvant chemotherapy in the management of locally advanced cervix cancer: a systematic review","volume":"8","author":"Osman","year":"2014","journal-title":"Oncol Rev"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/65\/6\/733\/60942328\/rrae073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/65\/6\/733\/60942328\/rrae073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:43:47Z","timestamp":1733859827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/65\/6\/733\/7810924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,10,5]]},"published-print":{"date-parts":[[2024,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrae073","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,10,5]]}}}